Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Details)

v3.19.1
SEGMENT INFORMATION (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
segment
Dec. 31, 2017
USD ($)
Segment Reporting Information [Line Items]    
Number of reportable segments | segment 2  
Product sales, net $ 48,244 $ 20,679
Gross Profit 33,878 14,489
Research and development 1,885 724
Selling, general and administrative 21,746 16,193
Royalty buy-out 0 2,432
Operating Income (Loss) 10,247 (4,860)
Goodwill 2,788 2,788
Consumer Products [Member]    
Segment Reporting Information [Line Items]    
Product sales, net 48,244 20,679
Gross Profit 33,878 14,489
Research and development 1,008 251
Selling, general and administrative 21,697 15,957
Royalty buy-out   2,432
Operating Income (Loss) 11,173 (4,151)
Specialty Pharmaceuticals [Member]    
Segment Reporting Information [Line Items]    
Product sales, net 0 0
Gross Profit 0 0
Research and development 877 473
Selling, general and administrative 49 236
Royalty buy-out   0
Operating Income (Loss) (926) (709)
Goodwill 2,788 2,788
Intangible assets $ 3,801 $ 3,836